{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:09:50Z","timestamp":1791274190242,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunoglobulin A nephropathy (IgAN) is not only the most common primary glomerular disease but also a chronic inflammatory condition associated with increased cardiometabolic risk through the cardiorenal axis. Persistent proteinuria and progressive renal dysfunction are linked to adverse cardiovascular and metabolic outcomes and may complicate the delivery of long-term lifestyle and nutritional risk\u2013modifying strategies. Telitacicept, a dual BAFF\/APRIL inhibitor, has emerged as a targeted immunomodulatory therapy for IgAN, yet the clinical evidence remains heterogeneous.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a scoping review of clinical studies evaluating telitacicept in biopsy-confirmed IgAN. PubMed, Embase, the Cochrane Central Register of Controlled Trials, and\n                      <jats:uri>ClinicalTrials.gov<\/jats:uri>\n                      were searched from inception to 2 January 2026. Randomized and observational studies reporting renal outcomes were included. When available, cardiometabolic- and nutrition-related variables (e.g., blood pressure, lipid profile, uric acid, body weight\/BMI, inflammatory markers, and lifestyle\/nutritional counseling) were also captured.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-four studies were identified, including one randomized controlled trial, 16 observational studies, and seven case reports\/series. Across studies, telitacicept consistently reduced proteinuria (approximately 49\u201387%) while maintaining stable estimated glomerular filtration rate. Additional reported benefits included improvements in serum albumin-likely reflecting reduced urinary protein loss\u2014and glucocorticoid-sparing effects. The therapy was generally well tolerated, with predominantly mild adverse events. Notably, cardiometabolic and nutritional endpoints were inconsistently reported across the current literature, limiting definitive conclusions regarding these outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence suggests that telitacicept may offer a promising targeted therapeutic option for IgAN by achieving sustained proteinuria reduction and renal function stabilization. From a clinical practice perspective, improved renal and inflammatory control may facilitate the implementation of long-term nutritional and metabolic risk\u2013modifying strategies in high-risk IgAN populations; however, direct evidence linking telitacicept to cardiometabolic or nutritional endpoints remains scarce. Larger, long-term randomized studies incorporating prespecified cardiometabolic and nutritional outcomes are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1790988","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:38:01Z","timestamp":1773758281000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune-mediated renal injury and cardiometabolic risk in IgA nephropathy: clinical evidence on telitacicept from a scoping review"],"prefix":"10.3389","volume":"13","author":[{"given":"Li","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing Genertec Aerospace Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Genertec Aerospace Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chumeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Genertec Aerospace Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Genertec Aerospace Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhai","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Beijing Genertec Aerospace Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Beijing Genertec Aerospace Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/ki.2015.252","article-title":"New developments in the genetics, pathogenesis, and therapy of IgA nephropathy","volume":"88","author":"Magistroni","year":"2015","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1681\/ASN.2018101017","article-title":"Mortality in IgA nephropathy: a nationwide population-based cohort study","volume":"30","author":"Jarrick","year":"2019","journal-title":"J Am Soc Nephrol: JASN"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA nephropathy: core curriculum 2021","volume":"78","author":"Pattrapornpisut","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol: JASN"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1523-1755.2005.00390.x","article-title":"Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy","volume":"68","author":"Xu","year":"2005","journal-title":"Kidney Int"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fimmu.2016.00117","article-title":"The origin and activities of IgA1-containing immune complexes in IgA nephropathy","volume":"7","author":"Knoppova","year":"2016","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment. Nature reviews","volume":"21","author":"Cheung","year":"2025","journal-title":"Nephrology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMc2401277","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41232-016-0015-4","article-title":"BAFF- and APRIL-targeted therapy in systemic autoimmune diseases","volume":"36","author":"Nakayamada","year":"2016","journal-title":"Inflam Regenerat"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of Telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"sfaf154","DOI":"10.1093\/ckj\/sfaf154","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes","volume":"18","author":"Weng","year":"2025","journal-title":"Clin Kidney J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"sfaf261","DOI":"10.1093\/ckj\/sfaf261","article-title":"Telitacicept versus mycophenolate mofetil in IgA nephropathy: a real-world comparative study of efficacy, renal outcomes and safety","volume":"18","author":"He","year":"2025","journal-title":"Clin Kidney J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2449580","DOI":"10.1080\/0886022X.2025.2449580","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: a real-world study","volume":"47","author":"Dong","year":"2025","journal-title":"Ren Fail"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1642137","DOI":"10.3389\/fphar.2025.1642137","article-title":"Efficacy and safety of telitacicept in the treatment of IgA nephropathy: a single-center, real-world study","volume":"16","author":"Tao","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ekir.2024.11.1363","article-title":"Efficacy and safety of telitacicept as an add-on therapy for refractory immunoglobulin a nephropathy or immunoglobulin a vasculitis nephropathy in children","volume":"10","author":"Liu","year":"2025","journal-title":"Kidney Int Rep"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1007\/s00467-025-06905-z","article-title":"Efficacy and safety of telitacicept in IgA nephropathy and IgA vasculitis nephropathy in adolescents: a case series","volume":"40","author":"Wu","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10238-025-01829-2","article-title":"Telitacicept plus low-dose mycophenolate mofetil in the treatment of IgA nephropathy: a retrospective study","volume":"25","author":"Shu","year":"2025","journal-title":"Clin Exp Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"sfaf232","DOI":"10.1093\/ckj\/sfaf232","article-title":"Telitacicept treatment for recurrent IgA nephropathy after kidney transplantation","volume":"18","author":"Xu","year":"2025","journal-title":"Clin Kidney J"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e9553","DOI":"10.1002\/ccr3.9553","article-title":"Single-dose telitacicept therapy for refractory idiopathic membranous nephropathy: a case series","volume":"12","author":"Sun","year":"2024","journal-title":"Clin Case Reports"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12969-025-01159-3","article-title":"Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study","volume":"23","author":"Ma","year":"2025","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-025-07023-6","article-title":"Efficacy and safety of telitacicept in the treatment of pediatric IgA nephropathy: a retrospective study","author":"Jin","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000540326","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: a retrospective, multicenter study","volume":"149","author":"Liu","year":"2025","journal-title":"Nephron"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"sfae285","DOI":"10.1093\/ckj\/sfae285","article-title":"Efficacy and safety of telitacicept, a BLyS\/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study","volume":"17","author":"Wang","year":"2024","journal-title":"Clin Kidney J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1667519","DOI":"10.3389\/fmed.2025.1667519","article-title":"Telitacicept administration improved immunoglobulin a nephropathy after hematopoietic stem cell transplantation: a case report","volume":"12","author":"Yuan","year":"2025","journal-title":"Front Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1007\/s00467-025-06709-1","article-title":"Telitacicept use in children with IgA vasculitis nephritis: preliminary observations","volume":"40","author":"Wang","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00467-025-06769-3","article-title":"Telitacicept as a BAFF\/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis","volume":"40","author":"Jin","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1571616","DOI":"10.3389\/fmed.2025.1571616","article-title":"Telitacicept monotherapy for refractory idiopathic membranous nephropathy: a case report and literature review","volume":"12","author":"Chen","year":"2025","journal-title":"Front Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.12998\/wjcc.v12.i29.6307","article-title":"Combination treatment with telitacicept, mycophenolate mofetil and glucocorticoids for immunoglobulin a nephropathy: a case report","volume":"12","author":"Shen","year":"2024","journal-title":"World J Clin Cases"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12882-025-04468-7","article-title":"Effectiveness and safety of telitacicept in IgA nephropathy: a propensity score matching analysis with a 6-month follow-up","volume":"26","author":"Li","year":"2025","journal-title":"BMC Nephrol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"sfaf251","DOI":"10.1093\/ckj\/sfaf251","article-title":"Novel therapies improve prognosis of IgAN and limit the applicability of the international IgA nephropathy prediction tool","volume":"18","author":"Shen","year":"2025","journal-title":"Clin Kidney J"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/cpdd.1136","article-title":"Pharmacokinetic characteristics, safety, and tolerability of telitacicept, an injectable recombinant human B-lymphocyte stimulating factor receptor-antibody fusion protein, in healthy Chinese subjects","volume":"11","author":"Xie","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"103291","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J Autoimmun"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s40001-023-01320-2","article-title":"Role of telitacicept in the treatment of IgA nephropathy","volume":"28","author":"Wu","year":"2023","journal-title":"Eur J Med Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the Management of Glomerular Diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.11.004","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2165\/00002018-200730100-00005","article-title":"Corticosteroid-induced adverse events in adults: frequency, screening and prevention","volume":"30","author":"Fardet","year":"2007","journal-title":"Drug Saf"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"20251158","DOI":"10.1515\/biol-2025-1158","article-title":"A case of IgA nephropathy treated with a combination of telitacicept and half-dose glucocorticoids","volume":"20","author":"Zhang","year":"2025","journal-title":"Open Life Sci"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1564242","DOI":"10.3389\/fimmu.2025.1564242","article-title":"Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12884-024-06632-7","article-title":"Successful pregnancy in a patient with IgA nephropathy treated with telitacicept: a case report","volume":"24","author":"Du","year":"2024","journal-title":"BMC Pregnancy Childbirth"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1790988\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:38:02Z","timestamp":1773758282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1790988\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":45,"alternative-id":["10.3389\/fnut.2026.1790988"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1790988","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"article-number":"1790988"}}